Search alternatives:
point decrease » point increase (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 point » _ point (Expand Search)
point decrease » point increase (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 point » _ point (Expand Search)
-
81
-
82
Population dynamics modeling of split<sup>50cM</sup> <i>ClvR</i> V1 drive introduced at different release percentages, and an example illustrating the role that LOF alleles play in...
Published 2021“…A large number of individuals WT at each of these loci is now introduced into the modified population (release of 50%). …”
-
83
-
84
-
85
Fenretinide decreases levels of PAX3/FOXO1 and its target genes in aRMS cell lines.
Published 2013“…D) Fenretinide did not decrease mRNA levels of FOXO1 in aRMS cells. qRT–PCR was carried out after treatment with an IC<sub>50</sub> concentration of fenretinide during different time points (24–48–72 hours). …”
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.
Published 2016“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
-
96
-
97
-
98
-
99
-
100